Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first subcutaneous formulation for EGFR-mutated NSCLC.
Key clinical highlights: SC administration reduces infusion time to ~5 minutes, showed an ARR rate of 13% vs 66% for IV, lower VTE incidence (11% vs 18%), and PK comparability per Phase 3 PALOMA-3. Combined with LAZCLUZE, prior MARIPOSA data showed a statistically significant OS benefit (HR 0.75; 95% CI 0.61–0.92; P=0.0048) at 37.8-month median follow-up; median OS was not reached and is projected to exceed four years.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. ET on Wednesday, January 21 to review fourth-quarter results. The call will be led by Joaquin Duato, CEO; Joseph J. Wolk, CFO; and Darren Snellgrove, VP Investor Relations, with additional executives joining the Q&A.
Investors can access the live webcast and presentation at www.investor.jnj.com. A webcast replay will be available about three hours after the call and by telephone until ~12:00 a.m. on February 4. The press release will be posted at ~6:45 a.m. ET the morning of the call. The company also notes the first-quarter 2026 date of Tuesday, April 14, 2026.
Johnson & Johnson (NYSE:JNJ) announced U.S. FDA approval on Dec 13, 2025 for AKEEGA® (niraparib + abiraterone acetate) plus prednisone for BRCA2‑mutated metastatic castration‑sensitive prostate cancer (mCSPC).
Approval was based on Phase 3 AMPLITUDE results showing AKEEGA plus ADT reduced risk of radiographic progression or death by 54% (HR 0.46; 95% CI 0.32–0.66) and delayed symptomatic progression by 59% (HR 0.41; 95% CI 0.29–0.65).
The safety profile matched known monotherapy risks; common adverse reactions (≥20%) included hematologic abnormalities, fatigue, musculoskeletal pain, and hypertension.
Johnson & Johnson (NYSE:JNJ) reported Phase 3 MajesTEC-3 results showing TECVAYLI plus DARZALEX FASPRO significantly improved survival and response versus standard RRMM regimens at nearly three years follow-up.
Key outcomes: PFS HR 0.17 (83% risk reduction; P<0.0001), OS HR 0.46 (3-year OS 83.3% vs 65.0%), higher complete response (81.8% vs 32.1%), and higher MRD-negativity (58.4% vs 17.1%).
Safety: similar Grade 3/4 TEAE rates; higher infection rates but reduced after six months with prophylaxis.
Regulatory: sBLA submitted; U.S. FDA granted Breakthrough Therapy Designation and review via RTOR.
Johnson & Johnson (NYSE: JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast will be available on Johnson & Johnson’s Investor Relations website at www.investor.jnj.com, with an archived edition published later the same day. The audio webcast replay will be available approximately 48 hours after the live event.
Johnson & Johnson (NYSE: JNJ) reported updated CARTITUDE-4 Phase 3 results showing durable, treatment-free remissions with CARVYKTI as early as second line for relapsed or refractory multiple myeloma. In the as-treated standard-risk subgroup, the 30-month progression-free survival (PFS) rate plateaued at 80.5% (95% CI, 67.2–88.8) after a single infusion (median follow-up 33.6 months).
Of 176 patients treated in second line, 59 had standard-risk cytogenetics; all 26 patients who were MRD-negative CR at 12 months remained progression-free at 30 months. Translational analyses linked earlier-line use to stronger immune fitness (increased baseline CD4+ naïve T cells), which correlated with longer PFS.
Johnson & Johnson (NYSE:JNJ) reported Cohort 4 results from the Phase 2b SunRISe-1 study showing the gemcitabine intravesical system produced a one-year disease-free survival (DFS) of 74.3% (95% CI, 59.2-84.6) in BCG-unresponsive, high-risk, papillary-only NMIBC patients.
At median follow-up of 15.9 months, one-year progression-free survival was 95.6% and overall survival was 98%. 92.3% of patients did not undergo radical cystectomy. Treatment was generally well tolerated, with mostly low-grade urinary side effects and no treatment-related deaths.
Johnson & Johnson (NYSE: JNJ) partnered with Naomi Watts on Dec. 3, 2025 to promote eye exams as part of self-care for people over 40. A new global survey found 82% of Americans say clear vision supports confidence, yet 48% of those over 40 who think they need vision correction haven't seen an eye care professional in the past year. The release highlights presbyopia (begins ~age 40), cataracts, and that an annual eye exam can detect 270+ health conditions. The campaign urges routine comprehensive eye exams, modern corrective options, and talking to a doctor to preserve vision and independence.
TREMFYA (guselkumab) received FDA approval for a subcutaneous (SC) induction regimen to treat adults with moderately to severely active ulcerative colitis (UC) on Sept. 19, 2025.
Approval follows Phase 3 ASTRO data showing SC induction (400 mg q4w) produced clinical remission 26% vs 7% and endoscopic improvement 36% vs 12% versus placebo at Week 12, with comparable efficacy to previously approved 200 mg IV induction. Week 24 SC maintenance rates included clinical remission 34% vs 10% and endoscopic improvement up to 44% vs 12%. The company also announced a head-to-head Crohn's disease study vs Skyrizi (risankizumab).
Johnson & Johnson (NYSE: JNJ) reported Phase 3b APEX data showing TREMFYA (guselkumab) significantly inhibited structural joint damage in active psoriatic arthritis through Week 48 and reduced radiographic progression by 57% for placebo-switch patients from Week 24–48 (mean vdH-S 0.96 to 0.41).
TREMFYA showed ~2.5x greater inhibition versus placebo at Week 24, sustained at Week 48, and more than half of treated patients across dose groups achieved ACR50 by Week 48. Safety was consistent with the established profile and no new signals were identified. JNJ submitted an sBLA to FDA to add inhibition-of-structural-damage data to the label.